Economic implications of nesiritide versus dobutamine in the treatment of patients with acutely decompensated congestive heart failure
Author/Authors :
Gregory de Lissovoy، نويسنده , , Gregory and Stier، نويسنده , , David M. and Ciesla، نويسنده , , Gabrielle and Munger، نويسنده , , Mark S. Burger، نويسنده , , Andrew J.، نويسنده ,
Issue Information :
روزنامه با شماره پیاپی سال 2003
Pages :
3
From page :
631
To page :
633
Abstract :
Pooled data from trials comparing nesiritide with dobutamine for treatment of acute decompensated congestive heart failure were combined with national hospital cost data in an economic model. Results indicate that the acquisition cost of nesiritide is fully offset by decreased hospital costs.
